127 related articles for article (PubMed ID: 34338562)
21. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.
Samy N; Hashim M; Sayed M; Said M
Dis Markers; 2009; 26(4):163-70. PubMed ID: 19729797
[TBL] [Abstract][Full Text] [Related]
22. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
Anik Ilhan G; Yildizhan B; Pekin T
Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
[TBL] [Abstract][Full Text] [Related]
23. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome.
González F; Rote NS; Minium J; Kirwan JP
J Clin Endocrinol Metab; 2006 Apr; 91(4):1508-12. PubMed ID: 16464947
[TBL] [Abstract][Full Text] [Related]
24. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
Durmus U; Duran C; Ecirli S
J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
[TBL] [Abstract][Full Text] [Related]
25. Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome.
Erol O; Özel MK; Ellidağ HY; Toptaş T; Derbent AU; Yılmaz N
J Obstet Gynaecol; 2017 Jul; 37(5):633-638. PubMed ID: 28319674
[TBL] [Abstract][Full Text] [Related]
26. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.
González F; Rote NS; Minium J; Kirwan JP
J Clin Endocrinol Metab; 2006 Jan; 91(1):336-40. PubMed ID: 16249279
[TBL] [Abstract][Full Text] [Related]
27. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome.
González F; Rote NS; Minium J; Kirwan JP
J Endocrinol; 2006 Mar; 188(3):521-9. PubMed ID: 16522732
[TBL] [Abstract][Full Text] [Related]
28. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS.
Caglar GS; Kahyaoglu I; Pabuccu R; Demirtas S; Seker R
Arch Gynecol Obstet; 2013 Oct; 288(4):905-10. PubMed ID: 23553200
[TBL] [Abstract][Full Text] [Related]
29. Relation of NT-probnp levels and cardiovascular disease risk factors in lean women with polycystic ovary syndrome.
Karadağ C; Yoldemir T
J Obstet Gynaecol; 2019 Nov; 39(8):1154-1159. PubMed ID: 31215274
[TBL] [Abstract][Full Text] [Related]
30. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.
Vgontzas AN; Trakada G; Bixler EO; Lin HM; Pejovic S; Zoumakis E; Chrousos GP; Legro RS
Metabolism; 2006 Aug; 55(8):1076-82. PubMed ID: 16839844
[TBL] [Abstract][Full Text] [Related]
31. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls.
Huddleston HG; Quinn MM; Kao CN; Lenhart N; Rosen MP; Cedars MI
Clin Endocrinol (Oxf); 2017 Dec; 87(6):775-782. PubMed ID: 29044581
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
33. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS.
Li L; Zhang F; Cui J; Shi Y; Xiang J; Wang X; Zhao N; Yan Q; Greenberg AS; Peng Y; Ding X
Gynecol Endocrinol; 2017 Mar; 33(3):238-243. PubMed ID: 27960599
[TBL] [Abstract][Full Text] [Related]
34. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome.
Sayin NC; Gücer F; Balkanli-Kaplan P; Yüce MA; Ciftci S; Kücük M; Yardim T
J Reprod Med; 2003 Mar; 48(3):165-70. PubMed ID: 12698773
[TBL] [Abstract][Full Text] [Related]
35. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
36. Association between inflammatory biomarker serum procalcitonin and obesity in women with polycystic ovary syndrome.
Rashad NM; El-Shal AS; Abdelaziz AM
J Reprod Immunol; 2013 Apr; 97(2):232-9. PubMed ID: 23218400
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.
Gonzalez F; Thusu K; Abdel-Rahman E; Prabhala A; Tomani M; Dandona P
Metabolism; 1999 Apr; 48(4):437-41. PubMed ID: 10206434
[TBL] [Abstract][Full Text] [Related]
38. Are progranulin levels associated with polycystic ovary syndrome and its possible metabolic effects in adolescents and young women?
Ersoy AO; Tokmak A; Ozler S; Oztas E; Ersoy E; Celik HT; Erdamar H; Yilmaz N
Arch Gynecol Obstet; 2016 Aug; 294(2):403-9. PubMed ID: 27071619
[TBL] [Abstract][Full Text] [Related]
39. The Role of Visceral Adiposity Index as Predictor of Metabolic Syndrome in Obese and Nonobese Women with Polycystic Ovary Syndrome.
de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW
Metab Syndr Relat Disord; 2021 Feb; 19(1):18-25. PubMed ID: 32845813
[No Abstract] [Full Text] [Related]
40. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study.
Thathapudi S; Kodati V; Erukkambattu J; Katragadda A; Addepally U; Hasan Q
Genet Test Mol Biomarkers; 2014 Sep; 18(9):605-9. PubMed ID: 25083576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
